Investors Urged to Take Action in PomDoctor Securities Fraud Case Ahead of Deadline

PomDoctor Ltd. Securities Fraud Lawsuit: A Call to Action for Investors

PomDoctor Ltd. (NASDAQ: POM) is facing allegations of securities fraud that have serious implications for its investors. According to the Rosen Law Firm, a prominent global law firm specializing in investor rights, those who purchased securities of PomDoctor between October 9, 2025, and December 11, 2025, are encouraged to take action before the crucial deadline of April 7, 2026, to ensure their representation in the upcoming class action lawsuit.

## What You Need to Know

The looming April 7 deadline marks the last chance for investors to file as lead plaintiffs in this case. Investors who acquired PomDoctor securities during the specified class period may be eligible for compensation without incurring direct fees or costs, thanks to a contingency fee arrangement. This means that the firm only gets paid if the plaintiffs win the case, making it a risk-free opportunity for investors.

If you purchased PomDoctor securities during this period, it’s crucial to act swiftly if you wish to participate in the class action. To get involved, you can fill out a form on the Rosen Law Firm's website or reach out directly to Phillip Kim, Esq., at 866-767-3653. An active class action has already been filed, aiming to hold the company accountable for misleading practices.

Why Join the Class Action?

Several allegations have surfaced regarding PomDoctor that investors need to be aware of. According to the lawsuit, numerous misleading statements and omissions were made by the company, providing false reassurance about its business practices. Claims include:
1. Stock Promotion Schemes: The defendants are accused of participating in a fraudulent stock promotion scheme that utilized social media misinformation and impersonated financial professionals to inflate stock prices.
2. Insider Activity: Insiders and affiliates allegedly used offshore accounts to facilitate significant shares dumping during the period when the company’s stock was artificially inflated.
3. Hidden Risks: PomDoctor failed to disclose critical risk factors, including the influence of false rumors and manipulated trading activity that impacted stock prices.
4. Deceptive Statements: The lawsuit states that RossDoctor’s optimistic public statements regarding their operations and growth prospects lacked a reasonable basis due to these undisclosed issues.

Importance of Qualified Counsel

The Rosen Law Firm emphasizes the necessity of selecting legal representation with a proven track record in successfully handling securities class actions. Many law firms merely act as intermediaries without actively litigating such cases. As a result, investors are encouraged to choose counsel with expertise and recognition in securities law.

Rosen Law Firm has previously achieved significant recoveries on behalf of investors, including a record-setting settlement in a case involving a Chinese company. According to statistics, the firm was ranked number one in securities class action settlements in 2017 and has maintained high rankings year after year. This experience increases the likelihood of a successful outcome for investors involved in the PomDoctor case.

How to Proceed

To join the class action lawsuit against PomDoctor, visit Rosen Law Firm's submission page or contact Phillip Kim, Esq. for more details. Keep in mind that until a class is officially certified, you won’t be represented unless you secure legal counsel on your own. You may choose to remain a passive class member and take no action at this time if that suits your preference.

Follow-Up & Updates

Stay informed about the progress and updates regarding this class action lawsuit by following the Rosen Law Firm on their social media accounts including LinkedIn, Twitter, and Facebook. These platforms provide valuable information and timely updates for potential plaintiffs.

In summary, for those affected by PomDoctor's actions, the time to act is now. With the April 7 deadline approaching, ensuring representation and potentially receiving compensation is critical in this ongoing case of alleged securities fraud.